Three studies examine how resistance to chemotherapy develops in cancers deficient in BRCA1 and BRCA2. The mechanism involves restoration of BRCA1 and BRCA2 activity. Shah examines the implications for the clinic, such as the potential value of continuing treatment with cisplatin and similar agents even after drug resistance develops.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sakai, W. et al. Nature 451, 1116–1120 (2008).
Edwards, S.L. et al. Nature 451, 1111–1115 (2008).
Swisher, E.M. et al. Cancer Res. 68, 2581–2586 (2008).
Aletti, G.D., Gallenberg, M.M., Cliby, W.A., Jatoi, A. & Hartmann, L.C. Mayo Clin. Proc. 82, 751–770 (2007).
Farmer, H. et al. Nature 434, 917–921 (2005).
Bryant, H.E. et al. Nature 434, 913–917 (2005).
Taniguchi, T. et al. Nat. Med. 9, 568–574 (2003).
Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Shah, N.P. & Sawyers, C.L. Oncogene 22, 7389–7395 (2003).
Skorski, T. Oncogene 21, 8591–8604 (2002).
Druker, B.J. et al. N. Engl. J. Med. 355, 2408–2417 (2006).
Shah, N.P. et al. J. Clin. Invest. 117, 2562–2569 (2007).
Herzog, T.J., Coleman, R.L., Markman, M., Cella, D. & Thigpen, J.T. Gynecol. Oncol. 102, 218–225 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
N.P.S. has served as a consultant for Bristol-Myers Squibb (manufacturer of cisplantin) and Novartis (manufacturer of imatinib).
Rights and permissions
About this article
Cite this article
Shah, N. BRCA: From therapeutic target to therapeutic shield. Nat Med 14, 495–496 (2008). https://doi.org/10.1038/nm0508-495
Issue Date:
DOI: https://doi.org/10.1038/nm0508-495
